Medicinal cannabis as a whole is back, so AEB will benefit too. However, whilst the repositioning of this company is good, some things in that report need further explanations.
Now does this mean AEB will not 300% in 3 weeks? Not at all.
There are just more questions that need to be asked: What about the Indian plant project? What about the capital required to become a grower? Fully automated growing? How will that not be capital intensive? Where are the sales of the gencore offtake or aquarium range or amazon sales? Doubling efficiency in production and nothing is getting sold?
Either they're planning an explosive end of calendar year (possible) either there is a big issue somewhere.
This unfortunately just confirms AEB is high risk. Big debt, big plans to become a grower... and no sales, news on the big projects like the 100m indian facility?
Get into F biofuel and hemp for cattle. It's there.
